Oral antidiabetic medications - Dipeptidyl peptidase-4 (DPP-4) inhibitors: Nursing Pharmacology

Dipeptidyl peptidase-4 inhibitors, or DPP4 inhibitors for short, are medications used to treat type 2 diabetes mellitus. Type 2 diabetes mellitus is characterized by insulin resistance, which is when tissue cells have trouble responding to insulin in order to use glucose from the blood.

As a result, tissue cells starve for energy despite having high blood glucose levels, which is called hyperglycemia. Now, commonly used DPP4 inhibitors are sitagliptin, saxagliptin, linagliptin, and alogliptin. All of them end with the suffix -gliptin, which makes them easy to recognize!

DPP4 inhibitors are taken orally. Once administered, these medications inhibit the enzyme DPP4, which normally destroys the hormone incretin.

As a result, DPP4 inhibitors increase the levels of incretin, which in turn increases insulin secretion and decreases glucagon secretion. The end result is a reduction in glucose production by the liver, and thus a reduction in blood glucose levels.

Now, the most common side effects of DPP4 inhibitors include headaches, nausea, vomiting, and diarrhea or constipation, as well as mild infections of the upper respiratory or urinary tract.

In addition, they can increase the risk of hypoglycemia, pancreatitis, and acute renal failure. Less frequently, DPP4 inhibitors can cause life-threatening side effects, such as anaphylaxis, angioedema or Stevens Johnson syndrome.

As far as contraindications go, DPP4 inhibitors should not be used in clients with a history of pancreatitis, hypoglycemia, and angioedema.